Agency Information Collection Activities: Proposed Collection; Comment Request, 18411-18412 [2024-05291]
Download as PDF
Federal Register / Vol. 89, No. 50 / Wednesday, March 13, 2024 / Notices
FEDERAL RESERVE SYSTEM
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
Centers for Medicare & Medicaid
Services
lotter on DSK11XQN23PROD with NOTICES1
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than April 12, 2024.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414.
Comments can also be sent
electronically to
Comments.applications@chi.frb.org:
1. Billfloat, Inc., dba SmartBiz Loans,
San Francisco, California; to become a
bank holding company by acquiring
United Community Bancshares, Inc.,
and thereby indirectly acquiring
Centrust Bank, N.A., both of
Northbrook, Illinois.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–05323 Filed 3–12–24; 8:45 am]
BILLING CODE 6210–01–P
VerDate Sep<11>2014
17:33 Mar 12, 2024
Jkt 262001
[Document Identifiers: CMS–10279, CMS–
10316 and CMS–10008]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
May 13, 2024.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
18411
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10279 Ambulatory Surgical
Center Conditions for Coverage
CMS–10316 Implementation of the
Medicare Prescription Drug Plan
(PDP) and Medicare Advantage
(MA) Plan Disenrollment Reasons
Survey
CMS–10008 Transitional Pass-through
payments related to Drugs,
Biologicals, and
Radiopharmaceuticals to determine
eligibility under the Outpatient
Prospective Payment System
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Reinstatement with changes to
a previously approved collection; Title
of Information Collection: Ambulatory
Surgical Center Conditions for Coverage;
Use: The purpose of this package is to
request from the Office of Management
and Budget (OMB) the approval to
reinstate, with changes, the collection of
E:\FR\FM\13MRN1.SGM
13MRN1
lotter on DSK11XQN23PROD with NOTICES1
18412
Federal Register / Vol. 89, No. 50 / Wednesday, March 13, 2024 / Notices
information. The Cfc for ASCs are
regulation based on criteria described
and codified at § 42 CFR 416. The Cfc
establish standards designed to ensure
that each ASC has properly trained staff
to provide the appropriate type and
level of care for the environment of ASC
patients.
To determine ASC compliance with
CMS standards, CMS, via the Secretary,
authorizes States, through contracts, to
survey ASC facilities. For Medicare
purposes, certification is based on the
State survey agency’s recording of an
ASC provider’s compliance or noncompliance with the health and safety
Cfc as published and codified in 42 CFR
416.40 to 485.54. The information
collections aid surveyors as they assess
ASC compliance or non-compliance.
The previous iteration of this
information collection request had a
burden of 262,946 annual hours at an
annual cost of $28,144,370. For this
requested reinstatement, with changes,
the adjusted annual hourly burden is
97,527 hours at a cost of $11,089,427.
The reasons for this change, is the
previous iteration of this IC assumed the
development associated with IC–1 and
IC–2 occurred frequently. We have
revised this as development of drafts
only occur on a one-time basis. Form
Number: CMS–10279 (OMB control
number: 0938–1071); Frequency:
Annual; Affected Public: Business or
other for-profit and Not-for-profit
institutions; Number of Respondents:
6,257; Total Annual Responses: 6,257;
Total Annual Hours: 97,527. (For policy
questions regarding this collection
contact Claudia Molinar at 410–786–
8445.)
2. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Implementation
of the Medicare Prescription Drug Plan
(PDP) and Medicare Advantage (MA)
Plan Disenrollment Reasons Survey;
Use: Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (MMA) provides a requirement to
collect and report performance data for
Part D prescription drug plans.
Specifically, the MMA under Sec.
1860D–4 (Information to Facilitate
Enrollment) requires CMS to conduct
consumer satisfaction surveys regarding
the PDP and MA contracts pursuant to
section 1860D–4(d). Plan disenrollment
is generally believed to be a broad
indicator of beneficiary dissatisfaction
with some aspect of plan services, such
as access to care, customer service, cost
of the plan, services, benefits provided,
or quality of care.
This data collection complements the
enrollee beneficiary experience data
VerDate Sep<11>2014
17:33 Mar 12, 2024
Jkt 262001
collected through the Medicare
Consumer Assessment of Healthcare
Providers and Systems (Medicare
CAHPS) survey by providing
information on the reasons for
disenrollment from a Medicare
Advantage (with or without prescription
drug coverage) or Prescription Drug
Plan.
The Disenrollment Survey results are
an important source of information used
by CMS to monitor contract
performance and to identify potential
problems (e.g., plans providing incorrect
information to beneficiaries or creating
access problems). CMS uses the results
to monitor the quality of service that
Medicare beneficiaries get from
contracted plans and their providers
and to understand beneficiaries’
expectations relative to provided
benefits and services for MA and PDPs.
CMS uses information from the
Disenrollment Survey to support quality
improvement efforts of individual
contracts. Form Number: CMS–10316
(OMB control number: 0938–1113);
Frequency: Yearly; Affected Public:
Individuals and Households; Number of
Respondents: 36,050; Total Annual
Responses: 36,050; Total Annual Hours:
6,730. (For policy questions regarding
this collection contact Beth Simon at
415–744–3780.)
3. Type of Information Collection
Request: Extension currently approved
collection; Title of Information
Collection: Transitional Pass through
payments related to Drugs, Biologicals,
and Radiopharmaceuticals to determine
eligibility under the Outpatient
Prospective Payment System; Use:
Section 1833(t)(6)(D)(i) of the Act sets
the payment rate for pass-through
eligible drugs and biologicals (assuming
that no pro rata reduction in passthrough payment is necessary) as the
amount determined under section
1842(o) of the Act. Section 303(c) of
Public Law 108–173 amended Title
XVIII of the Act by adding new section
1847A. This new section establishes the
use of the average sales price (ASP)
methodology for payment for drugs and
biologicals described in section
1842(o)(1)(C) of the Act furnished on or
after January 1, 2005. Therefore, as we
stated in the November 15, 2004 Federal
Register (69 FR 65776), in CY 2005, we
will pay under the OPPS for drugs,
biologicals and radiopharmaceuticals
with pass-through status consistent with
the provisions of section 1842(o) of the
Act as amended by Public Law 108–173
at a rate that is equivalent to the
payment these drugs and biologicals
will receive in the physician office
setting, and established in accordance
with the methodology described in the
PO 00000
Frm 00042
Fmt 4703
Sfmt 9990
CY 2005 Physician Fee Schedule final
rule.
Interested parties such as hospitals,
pharmaceutical companies, and
physicians will apply for transitional
pass-through payment for drugs,
biologicals, and radiopharmaceuticals
used with services covered under the
hospital OPPS. After we receive all
requested information, we will evaluate
the information to determine if the
criteria for making a transitional passthrough payment are met and if an
interim healthcare common procedure
coding system (HCPCS) code for a new
drug, biological, or radiopharmaceutical
is necessary. We will advise the
applicant of our decision, and update
the hospital OPPS during its next
scheduled quarterly update to reflect
any newly approved drug, biological, or
radiopharmaceutical. Based on
experience gained in processing
transitional pass-through and new
technology applications, we have
reworded some of the statements for
clarity and have more clearly requested
information in a format that will allow
us to determine if the drug, biological,
or radiopharmaceutical meets the cost
significance test, as well as to estimate
the associated pass-through payment
amount. In addition, we have also
eliminated the requirement for
applicants to obtain a national Level II
HCPCS code prior to seeking
transitional pass-through payment
eligibility, or provide us with a copy of
their application for a national HCPCS
code, as we had originally required in
the April 7, 2000 final rule. Form
Number: CMS–10008 (OMB control
number: 0938–0802); Frequency: Once;
Affected Public: Private Sector, Business
or other for-profit and Not-for-profit
institutions; Number of Respondents:
35; Total Annual Responses: 35; Total
Annual Hours: 560. (For policy
questions regarding this collection
contact Andrew Wang at 410–786–
8233.)
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–05291 Filed 3–12–24; 8:45 am]
BILLING CODE 4120–01–P
E:\FR\FM\13MRN1.SGM
13MRN1
Agencies
[Federal Register Volume 89, Number 50 (Wednesday, March 13, 2024)]
[Notices]
[Pages 18411-18412]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05291]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-10279, CMS-10316 and CMS-10008]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (PRA), federal agencies are required to publish notice in
the Federal Register concerning each proposed collection of information
(including each proposed extension or reinstatement of an existing
collection of information) and to allow 60 days for public comment on
the proposed action. Interested persons are invited to send comments
regarding our burden estimates or any other aspect of this collection
of information, including the necessity and utility of the proposed
information collection for the proper performance of the agency's
functions, the accuracy of the estimated burden, ways to enhance the
quality, utility, and clarity of the information to be collected, and
the use of automated collection techniques or other forms of
information technology to minimize the information collection burden.
DATES: Comments must be received by May 13, 2024.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number: __, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, please access
the CMS PRA website by copying and pasting the following web address
into your web browser: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10279 Ambulatory Surgical Center Conditions for Coverage
CMS-10316 Implementation of the Medicare Prescription Drug Plan (PDP)
and Medicare Advantage (MA) Plan Disenrollment Reasons Survey
CMS-10008 Transitional Pass-through payments related to Drugs,
Biologicals, and Radiopharmaceuticals to determine eligibility under
the Outpatient Prospective Payment System
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: Reinstatement with
changes to a previously approved collection; Title of Information
Collection: Ambulatory Surgical Center Conditions for Coverage; Use:
The purpose of this package is to request from the Office of Management
and Budget (OMB) the approval to reinstate, with changes, the
collection of
[[Page 18412]]
information. The Cfc for ASCs are regulation based on criteria
described and codified at Sec. 42 CFR 416. The Cfc establish standards
designed to ensure that each ASC has properly trained staff to provide
the appropriate type and level of care for the environment of ASC
patients.
To determine ASC compliance with CMS standards, CMS, via the
Secretary, authorizes States, through contracts, to survey ASC
facilities. For Medicare purposes, certification is based on the State
survey agency's recording of an ASC provider's compliance or non-
compliance with the health and safety Cfc as published and codified in
42 CFR 416.40 to 485.54. The information collections aid surveyors as
they assess ASC compliance or non-compliance.
The previous iteration of this information collection request had a
burden of 262,946 annual hours at an annual cost of $28,144,370. For
this requested reinstatement, with changes, the adjusted annual hourly
burden is 97,527 hours at a cost of $11,089,427. The reasons for this
change, is the previous iteration of this IC assumed the development
associated with IC-1 and IC-2 occurred frequently. We have revised this
as development of drafts only occur on a one-time basis. Form Number:
CMS-10279 (OMB control number: 0938-1071); Frequency: Annual; Affected
Public: Business or other for-profit and Not-for-profit institutions;
Number of Respondents: 6,257; Total Annual Responses: 6,257; Total
Annual Hours: 97,527. (For policy questions regarding this collection
contact Claudia Molinar at 410-786-8445.)
2. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Implementation of
the Medicare Prescription Drug Plan (PDP) and Medicare Advantage (MA)
Plan Disenrollment Reasons Survey; Use: Medicare Prescription Drug,
Improvement, and Modernization Act of 2003 (MMA) provides a requirement
to collect and report performance data for Part D prescription drug
plans. Specifically, the MMA under Sec. 1860D-4 (Information to
Facilitate Enrollment) requires CMS to conduct consumer satisfaction
surveys regarding the PDP and MA contracts pursuant to section 1860D-
4(d). Plan disenrollment is generally believed to be a broad indicator
of beneficiary dissatisfaction with some aspect of plan services, such
as access to care, customer service, cost of the plan, services,
benefits provided, or quality of care.
This data collection complements the enrollee beneficiary
experience data collected through the Medicare Consumer Assessment of
Healthcare Providers and Systems (Medicare CAHPS) survey by providing
information on the reasons for disenrollment from a Medicare Advantage
(with or without prescription drug coverage) or Prescription Drug Plan.
The Disenrollment Survey results are an important source of
information used by CMS to monitor contract performance and to identify
potential problems (e.g., plans providing incorrect information to
beneficiaries or creating access problems). CMS uses the results to
monitor the quality of service that Medicare beneficiaries get from
contracted plans and their providers and to understand beneficiaries'
expectations relative to provided benefits and services for MA and
PDPs. CMS uses information from the Disenrollment Survey to support
quality improvement efforts of individual contracts. Form Number: CMS-
10316 (OMB control number: 0938-1113); Frequency: Yearly; Affected
Public: Individuals and Households; Number of Respondents: 36,050;
Total Annual Responses: 36,050; Total Annual Hours: 6,730. (For policy
questions regarding this collection contact Beth Simon at 415-744-
3780.)
3. Type of Information Collection Request: Extension currently
approved collection; Title of Information Collection: Transitional Pass
through payments related to Drugs, Biologicals, and
Radiopharmaceuticals to determine eligibility under the Outpatient
Prospective Payment System; Use: Section 1833(t)(6)(D)(i) of the Act
sets the payment rate for pass-through eligible drugs and biologicals
(assuming that no pro rata reduction in pass-through payment is
necessary) as the amount determined under section 1842(o) of the Act.
Section 303(c) of Public Law 108-173 amended Title XVIII of the Act by
adding new section 1847A. This new section establishes the use of the
average sales price (ASP) methodology for payment for drugs and
biologicals described in section 1842(o)(1)(C) of the Act furnished on
or after January 1, 2005. Therefore, as we stated in the November 15,
2004 Federal Register (69 FR 65776), in CY 2005, we will pay under the
OPPS for drugs, biologicals and radiopharmaceuticals with pass-through
status consistent with the provisions of section 1842(o) of the Act as
amended by Public Law 108-173 at a rate that is equivalent to the
payment these drugs and biologicals will receive in the physician
office setting, and established in accordance with the methodology
described in the CY 2005 Physician Fee Schedule final rule.
Interested parties such as hospitals, pharmaceutical companies, and
physicians will apply for transitional pass-through payment for drugs,
biologicals, and radiopharmaceuticals used with services covered under
the hospital OPPS. After we receive all requested information, we will
evaluate the information to determine if the criteria for making a
transitional pass-through payment are met and if an interim healthcare
common procedure coding system (HCPCS) code for a new drug, biological,
or radiopharmaceutical is necessary. We will advise the applicant of
our decision, and update the hospital OPPS during its next scheduled
quarterly update to reflect any newly approved drug, biological, or
radiopharmaceutical. Based on experience gained in processing
transitional pass-through and new technology applications, we have
reworded some of the statements for clarity and have more clearly
requested information in a format that will allow us to determine if
the drug, biological, or radiopharmaceutical meets the cost
significance test, as well as to estimate the associated pass-through
payment amount. In addition, we have also eliminated the requirement
for applicants to obtain a national Level II HCPCS code prior to
seeking transitional pass-through payment eligibility, or provide us
with a copy of their application for a national HCPCS code, as we had
originally required in the April 7, 2000 final rule. Form Number: CMS-
10008 (OMB control number: 0938-0802); Frequency: Once; Affected
Public: Private Sector, Business or other for-profit and Not-for-profit
institutions; Number of Respondents: 35; Total Annual Responses: 35;
Total Annual Hours: 560. (For policy questions regarding this
collection contact Andrew Wang at 410-786-8233.)
William N. Parham, III,
Director, Division of Information Collections and Regulatory Impacts,
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2024-05291 Filed 3-12-24; 8:45 am]
BILLING CODE 4120-01-P